According to the broker, it is adjusting its price target as it starts to assign value to the company' induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy platform, or '500 series' of cell products. The broker said INDs have now cleared for FT500 and FT516, marking the first induced pluripotent stem cell (iPSC)-derived cell product and first engineered iPSC-derived product, respectively, to reach the clinic.
Price: 15.33, Change: +1.26, Percent Change: +8.93
|Analysts Reduce Alleghany Corp's Q2, 2019, and 2020 ...|
|2019, and 2020 Estimates for United States Steel Low...|
|Extraction Oil & Gas' 2019, 2020, and Q2 Earnings Es...|
|Earnings Estimate for Viper Energy Partners in 2020 ...|
|Westlake Chemical's 2019, 2020, and Q2 Earnings Esti...|